Clinical Trials Browser

Recurrence, Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase 2 Unknown

49 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

65 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Phase 2 Unknown

82 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

Phase 2 Unknown

100 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

Phase 2 Unknown

150 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04771871 2022-02-18

TARMAC

Phase 2 Unknown

42 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2/3 Unknown

420 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03876886 2019-03-21

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Phase 3 Unknown

200 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01752686 2012-12-25

A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 3 Unknown

587 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01378533 2011-12-28

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Phase 3 Unknown

100 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Phase 2 Unknown

80 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

BELLA

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

NeoPATH

HIFU

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

TNBC

TARMAC

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer